## Glenn S Bauman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4923489/publications.pdf

Version: 2024-02-01

61984 40979 9,608 193 43 93 citations h-index g-index papers 199 199 199 9464 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 240-248.	3.9	21
2	Is Remote Learning as Effective as In-Person Learning for Contouring Education? A Prospective Comparison of Face-to-Face versus Online Delivery of the Anatomy and Radiology Contouring Bootcamp. International Journal of Radiation Oncology Biology Physics, 2022, 112, 590-599.	0.8	12
3	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	1.7	7
4	Effect of <sup>18</sup> F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	<b>7.</b> 3	16
5	On the Way for Patients with Prostate Cancer to the Best Use of PSMA. International Journal of Molecular Sciences, 2022, 23, 2478.	4.1	O
6	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer, 2022, 22, 251.	2.6	5
7	Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology. Brachytherapy, 2022, , .	0.5	1
8	Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol. Frontiers in Oncology, 2022, 12, 863848.	2.8	1
9	Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2022, 12, 265-282.	2.1	90
10	Impact of <sup>18</sup> F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology, 2022, 304, 600-608.	7.3	10
11	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
12	Development, Implementation, and Initial Participant Feedback of an Online Anatomy and Radiology Contouring Bootcamp in Radiation Oncology. Journal of Medical Education and Curricular Development, 2021, 8, 238212052110377.	1.5	4
13	Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide. Expert Review of Anticancer Therapy, 2021, 21, 641-655.	2.4	8
14	Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. BMC Cancer, 2021, 21, 405.	2.6	13
15	A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy. Brachytherapy, 2021, 20, 601-610.	0.5	3
16	American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer. Practical Radiation Oncology, 2021, 11, 163-165.	2.1	2
17	Case – Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation. Canadian Urological Association Journal, 2021, 15, E620-E621.	0.6	1
18	Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation. Physics and Imaging in Radiation Oncology, 2021, 19, 102-107.	2.9	О

#	Article	IF	CITATIONS
19	Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada. Frontiers in Oncology, 2021, 11, 722430.	2.8	5
20	Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82. European Urology, 2021, 80, e77-e78.	1.9	0
21	Rapid visual field progression in a patient with glaucoma as the presenting manifestation of sarcoidosis. American Journal of Ophthalmology Case Reports, 2021, 23, 101132.	0.7	o
22	Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial. Advances in Radiation Oncology, 2021, 6, 100734.	1.2	4
23	Implementation and evaluation of an online anatomy, radiology and contouring bootcamp for radiation therapists. Journal of Medical Imaging and Radiation Sciences, 2021, 52, 567-575.	0.3	O
24	Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes. EJNMMI Research, 2021, 11, 107.	2.5	2
25	Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. Advances in Radiation Oncology, 2020, 5, 212-220.	1.2	16
26	Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285–93. European Urology, 2020, 77, e67-e68.	1.9	1
27	The Singularity is Near(ish): Emerging Applications of Artificial Intelligence in Prostate Cancer Management. European Urology, 2020, 77, 293-295.	1.9	4
28	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
29	Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer, 2020, 20, 978.	2.6	9
30	Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 9054.	4.1	32
31	Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiotherapy and Oncology, 2020, 152, 42-48.	0.6	15
32	Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging. Radiotherapy and Oncology, 2020, 152, 34-41.	0.6	8
33	Beyond Oligometastases. International Journal of Radiation Oncology Biology Physics, 2020, 107, 253-256.	0.8	15
34	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2830-2838.	1.6	683
35	Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens. Scientific Reports, 2020, 10, 9911.	3.3	22
36	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. Advances in Radiation Oncology, 2020, 5, 965-977.	1.2	29

#	Article	IF	Citations
37	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	1.6	107
38	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
39	Automatic cancer detection on digital histopathology images of mid-gland radical prostatectomy specimens. Journal of Medical Imaging, 2020, 7, 1.	1.5	2
40	Stereotactic ablative radiotherapy for the comprehensive treatment of $4\hat{a}$ $\in$ "10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
41	A threeâ€gene DNA methylation biomarker accurately classifies early stage prostate cancer. Prostate, 2019, 79, 1705-1714.	2.3	24
42	A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis. Advances in Radiation Oncology, 2019, 4, 668-673.	1.2	15
43	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 943-947.	0.8	46
44	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup> F-Fluoromethylcholine or <sup>68</sup> Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 1253-1258.	5.0	24
45	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, The, 2019, 393, 2051-2058.	13.7	1,333
46	Prospective, Multisite, International Comparison of <sup>18</sup> F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup> Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine, 2019, 60, 794-800.	5.0	61
47	Characterization of clinical human prostate cancer lesions using 3.0â€T sodium MRI registered to Gleasonâ€graded wholeâ€mount histopathology. Journal of Magnetic Resonance Imaging, 2019, 49, 1409-1419.	3.4	8
48	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. Cureus, 2019, 11, e6394.	0.5	2
49	The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 76-83.	0.3	3
50	[18F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience. European Urology Focus, 2018, 4, 702-706.	3.1	21
51	68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 686-693.	3.1	195
52	Apparent transverse relaxation () on <scp>MRI</scp> as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 224-231.	1.8	5
53	18F-DCFPyL PET/CT in Oncocytoma. Clinical Nuclear Medicine, 2018, 43, 921-924.	1.3	7
54	Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based?. Radiation Oncology, 2018, 13, 43.	2.7	14

#	Article	IF	CITATIONS
55	Automatic cancer detection and localization on prostatectomy histopathology images. , 2018, , .		3
56	Development of a computer aided diagnosis model for prostate cancer classification on multi-parametric MRI. , $2018$ , , .		1
57	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.6	18
58	Optimization of brain metastases radiotherapy with TomoHDA. Medical Dosimetry, 2017, 42, 53-56.	0.9	0
59	Extreme hypofractionation for high-risk prostate cancer: Dosimetric correlations with rectal bleeding. Practical Radiation Oncology, 2017, 7, e457-e462.	2.1	11
60	Searching for wisdom in oncology care: A scoping review. Palliative and Supportive Care, 2017, 15, 384-400.	1.0	0
61	Accuracy Validation of an Automated Method for Prostate Segmentation in Magnetic Resonance Imaging. Journal of Digital Imaging, 2017, 30, 782-795.	2.9	22
62	Lessons learned from reirradiation of recurrent skull base meningioma: A case report and review of the literature. Advances in Radiation Oncology, 2017, 2, 1-5.	1.2	3
63	Initial Investigation into Microbleeds and White Matter Signal Changes following Radiotherapy for Low-Grade and Benign Brain Tumors Using Ultra-High-Field MRI Techniques. American Journal of Neuroradiology, 2017, 38, 2251-2256.	2.4	13
64	The "Dirty Harry―Approach. International Journal of Radiation Oncology Biology Physics, 2017, 99, 8.	0.8	0
65	Patient- and family-centered care: a qualitative exploration of oncologist perspectives. Supportive Care in Cancer, 2017, 25, 213-219.	2.2	12
66	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	1.6	521
67	Evaluation of CT Perfusion Biomarkers of Tumor Hypoxia. PLoS ONE, 2016, 11, e0153569.	2.5	7
68	Target margins in radiotherapy of prostate cancer. British Journal of Radiology, 2016, 89, 20160312.	2.2	39
69	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with $1\hat{a}\in$ metastases. Journal of Neuro-Oncology, 2016, 128, 431-436.	2.9	1
70	Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion. International Journal of Radiation Oncology Biology Physics, 2016, 96, 188-196.	0.8	26
71	Detecting tumor progression in glioma: current standards and new techniques. Expert Review of Anticancer Therapy, 2016, 16, 1177-1188.	2.4	18
72	Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. Journal of Medical Imaging, 2016, 3, 046002.	1.5	3

#	Article	IF	Citations
73	Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images. Biomarkers in Cancer, 2016, 8s2, BIC.S31801.	3.6	11
74	Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer. Journal of Urology, 2016, 196, 1105-1111.	0.4	17
75	Choosing Wisely? "lt's Complicated!― Practical Radiation Oncology, 2016, 6, 71-73.	2.1	1
76	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. Journal of Neuro-Oncology, 2016, 126, 327-336.	2.9	31
77	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
78	Unshielded asymmetric transmit-only and endorectal receive-only radiofrequency coil for <sup>23</sup> Na MRI of the prostate at 3 tesla. Journal of Magnetic Resonance Imaging, 2015, 42, 436-445.	3.4	7
79	A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 856-862.	0.8	63
80	Dynamic perfusion CT in brain tumors. European Journal of Radiology, 2015, 84, 2386-2392.	2.6	22
81	Survival prediction in high-grade gliomas using CT perfusion imaging. Journal of Neuro-Oncology, 2015, 123, 93-102.	2.9	16
82	Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. Journal of Clinical Oncology, 2015, 33, 332-339.	1.6	113
83	The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy. Prostate Cancer and Prostatic Diseases, 2015, 18, 358-364.	3.9	24
84	In Reply to Kishan etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1163.	0.8	0
85	Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods. Medical Physics, 2014, 41, 113503.	3.0	16
86	Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma. Journal of Medical Radiation Sciences, 2014, 61, 4-13.	1.5	7
87	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology, 2014, 32, 3810-3816.	1.6	894
88	Multiparametric MR imaging of prostate cancer foci: assessing the detectability and localizability of Gleason 7 peripheral zone cancers based on image contrasts., 2014,,.		1
89	Accuracy and variability of tumor burden measurement on multi-parametric MRI. , 2014, , .		0
90	In Regard to Lee. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1212-1213.	0.8	3

#	Article	IF	Citations
91	Systematic review of fractionated brain metastases radiotherapy. Journal of Radiation Oncology, 2014, 3, 29-41.	0.7	9
92	Optimization of tomotherapy treatment planning for patients with bilateral hip prostheses. Radiation Oncology, 2014, 9, 43.	2.7	11
93	Management of High-Grade Gliomas in the Elderly. Seminars in Radiation Oncology, 2014, 24, 279-288.	2.2	16
94	Improving Quantitative CT Perfusion Parameter Measurements Using Principal Component Analysis. Academic Radiology, 2014, 21, 624-632.	2.5	11
95	A dimensionless dynamic contrast enhanced MRI parameter for intra-prostatic tumour target volume delineation: initial comparison with histology. , 2014, , .		0
96	Metastatic brain cancer: prediction of response to whole-brain helical tomotherapy with simultaneous intralesional boost for metastatic disease using quantitative MR imaging features. , 2014, , .		0
97	CT Perfusion Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery in C6 Rat Gliomas. PLoS ONE, 2014, 9, e109781.	2.5	3
98	Systematic review of brain metastases prognostic indices. Practical Radiation Oncology, 2013, 3, 101-106.	2.1	21
99	Propensity-score matched pair comparison of whole brain with simultaneous in-field boost radiotherapy and stereotactic radiosurgery. Radiotherapy and Oncology, 2013, 106, 206-209.	0.6	16
100	Prostate Histopathology: Learning Tissue Component Histograms for Cancer Detection and Classification. IEEE Transactions on Medical Imaging, 2013, 32, 1804-1818.	8.9	96
101	Dosimetric and Radiobiological Consequences of Computed Tomography–Guided Adaptive Strategies for Intensity Modulated Radiation Therapy of the Prostate. International Journal of Radiation Oncology Biology Physics, 2013, 87, 874-880.	0.8	13
102	Boosting imaging defined dominant prostatic tumors: A systematic review. Radiotherapy and Oncology, 2013, 107, 274-281.	0.6	115
103	A Multiphase Validation of Atlas-Based Automatic and Semiautomatic Segmentation Strategies for Prostate MRI. International Journal of Radiation Oncology Biology Physics, 2013, 85, 95-100.	0.8	36
104	The Effect of Scan Duration on the Measurement of Perfusion Parameters in CT Perfusion Studies ofÂBrain Tumors. Academic Radiology, 2013, 20, 59-65.	2.5	18
105	Toward quantitative digital histopathology for prostate cancer: comparison of inter-slide interpolation methods for tumour measurement. Proceedings of SPIE, 2013, , .	0.8	3
106	3D prostate histology reconstruction: an evaluation of image-based and fiducial-based algorithms. Proceedings of SPIE, 2013, , .	0.8	1
107	3D prostate histology image reconstruction: Quantifying the impact of tissue deformation and histology section location. Journal of Pathology Informatics, 2013, 4, 31.	1.7	29
108	Prostate: Registration of Digital Histopathologic Images to in Vivo MR Images Acquired by Using Endorectal Receive Coil. Radiology, 2012, 263, 856-864.	7.3	62

#	Article	IF	Citations
109	3D reconstruction of prostate histology based on quantified tissue cutting and deformation parameters. Proceedings of SPIE, 2012, , .	0.8	5
110	TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open, 2012, 2, e001410.	1.9	47
111	Inter- and Intrafraction Uncertainty in Prostate Bed Image-Guided Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 402-407.	0.8	54
112	18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer and Prostatic Diseases, 2012, 15, 45-55.	3.9	139
113	In regard to Vargo et al: "Early Clinical Outcomes for 3 Radiation Techniques for Brain Metastases: Focal Versus Whole-Brain". Practical Radiation Oncology, 2012, 2, 155.	2.1	0
114	A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiotherapy and Oncology, 2012, 102, 180-186.	0.6	35
115	Assessment and improvement of radiation oncology trainee contouring ability utilizing consensus-based penalty metrics. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 679-688.	1.8	4
116	Categorizing segmentation quality using a quantitative quality assurance algorithm. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 668-678.	1.8	7
117	Extended Followup Oncologic Outcome of Randomized Trial Between Cryoablation and External Beam Therapy for Locally Advanced Prostate Cancer (T2c-T3b). Journal of Urology, 2012, 188, 1170-1175.	0.4	40
118	A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiation Oncology, 2012, 7, 42.	2.7	18
119	Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion. Medical Physics, 2012, 39, 1505-1517.	3.0	15
120	Registration of prostate histology images to ex vivo MR images via strandâ€shaped fiducials. Journal of Magnetic Resonance Imaging, 2012, 36, 1402-1412.	3.4	58
121	Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clinical and Translational Oncology, 2012, 14, 150-156.	2.4	36
122	Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. Journal of Neuro-Oncology, 2012, 107, 395-405.	2.9	61
123	Co-registration Framework for Histology-registration-based Validation of Fused Multimodality Prostate Cancer Imaging. , $2011, \ldots$		0
124	Pulmonary Tumor Measurements from X-Ray Computed Tomography inÂOne, Two, and Three Dimensions. Academic Radiology, 2011, 18, 1391-1402.	2.5	2
125	Evaluation of imageâ€guidance strategies with helical tomotherapy for localised prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 220-228.	1.8	15
126	Tissue block MRI for slice orientation-independent registration of digital histology images to ex vivo MRI of the prostate. , $2011,  ,  .$		4

#	Article	IF	CITATIONS
127	Technology assessment of automated atlas based segmentation in prostate bed contouring. Radiation Oncology, 2011, 6, 110.	2.7	45
128	Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1128-1133.	0.8	47
129	A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1306-1315.	0.8	37
130	Neurocytomas: Long-term experience of a single institution. Neuro-Oncology, 2011, 13, 943-949.	1.2	48
131	Validation of Direct Registration of Whole-Mount Prostate Digital Histopathology to ex vivo MR Images. Lecture Notes in Computer Science, 2011, , 134-145.	1.3	5
132	Simultaneous In-Field Boost for Brain Metastases: In Regard to Lagerwaard etÂal. (Int J Radiat Oncol) Tj ETQq0 0 964-965.	0 rgBT /O	verlock 10 Tf 2
133	Hippocampus avoidance with fan beam and volumetric arc radiotherapy for base of skull tumours. Journal of Radiotherapy in Practice, 2010, 9, 87-98.	0.5	1
134	Schedule for CT image guidance in treating prostate cancer with helical tomotherapy. British Journal of Radiology, 2010, 83, 241-251.	2.2	22
135	Radiosurgery scope of practice in Canada: A report of the Canadian association of radiation oncology (CARO) radiosurgery advisory committee. Radiotherapy and Oncology, 2010, 95, 122-128.	0.6	6
136	Molecular Targeted Enhanced Ultrasound Imaging of Flk1 Reveals Diagnosis and Prognosis Potential in a Genetically Engineered Mouse Prostate Cancer Model. Molecular Imaging, 2009, 8, 7290.2009.00020.	1.4	16
137	Dosimetric Comparison of Intensity-Modulated Radiosurgery and Helical Tomotherapy for the Treatment of Multiple Intracranial Metastases. Technology in Cancer Research and Treatment, 2009, 8, 361-367.	1.9	10
138	On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases. Radiation Oncology, 2009, 4, 2.	2.7	49
139	Adult Supratentorial Low-Grade Glioma: Long-Term Experience at a Single Institution. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1401-1407.	0.8	74
140	Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model. Molecular Imaging, 2009, 8, 209-20.	1.4	14
141	Comparing two strategies of dynamic intensity modulated radiation therapy (dlMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. Radiation Oncology, 2008, 3, 1.	2.7	31
142	Short Communication: Conformal Therapy for Peri-Ventricular Brain Tumors: Is Target Volume Deformation an Issue?. Medical Dosimetry, 2008, 33, 78-80.	0.9	0
143	Novel Application of Helical Tomotherapy in Whole Skull Palliative Radiotherapy. Medical Dosimetry, 2008, 33, 282-285.	0.9	8
144	Consistency Check of Planned Adaptive® Option on Helical Tomotherapy. Technology in Cancer Research and Treatment, 2008, 7, 425-432.	1.9	7

#	Article	IF	CITATIONS
145	Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 40-45.	3.9	51
146	3D Conformal Radiotherapy and Cisplatin for Recurrent Malignant Glioma. Canadian Journal of Neurological Sciences, 2008, 35, 57-64.	0.5	16
147	Segmentation and leaf sequencing for intensity modulated arc therapy. Medical Physics, 2007, 34, 1779-1788.	3.0	20
148	Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound. Cancer Research, 2007, 67, 2830-2839.	0.9	65
149	Simultaneous Infield Boost With Helical Tomotherapy for Patients With 1 to 3 Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 38-44.	1.3	41
150	Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health and Quality of Life Outcomes, 2007, 5, 29.	2.4	6
151	Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1238-1247.	0.8	224
152	A Prospective Evaluation of Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 632-641.	0.8	51
153	Adaptive Radiotherapy Planning on Decreasing Gross Tumor Volumes as Seen on Megavoltage Computed Tomography Images. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1316-1322.	0.8	146
154	Dosimetric evaluation of daily rigid and nonrigid geometric correction strategies during on-line image-guided radiation therapy (IGRT) of prostate cancer. Medical Physics, 2006, 34, 352-365.	3.0	41
155	Comparative planning evaluation of intensity-modulatedradiotherapy techniques for complex lung cancer cases. Radiotherapy and Oncology, 2006, 78, 169-176.	0.6	12
156	A comparison of prostate IMRT and helical tomotherapy class solutions. Radiotherapy and Oncology, 2006, 80, 374-377.	0.6	37
157	A simple technique for craniospinal radiotherapy in the supine position. Radiotherapy and Oncology, 2006, 80, 394.	0.6	4
158	Comparison of advanced irradiation techniques with photons for benign intracranial tumours. Radiotherapy and Oncology, 2006, 80, 268-273.	0.6	59
159	Fractionated Radiotherapy Techniques. Neurosurgery Clinics of North America, 2006, 17, 99-110.	1.7	6
160	Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: A radiobiologic analysis. International Journal of Radiation Oncology Biology Physics, 2006, 64, 289-300.	0.8	71
161	Serial megavoltage CT imaging during external beam radiotherapy for non–small-cell lung cancer: in regard to Kupelian et al. (Int J Radiat Oncol Biol Phys 2005;630:1024–1028). International Journal of Radiation Oncology Biology Physics, 2006, 64, 328.	0.8	3
162	Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 595-607.	0.8	68

#	Article	IF	Citations
163	Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag–Induced Transgenic Mouse Models. Molecular Cancer Research, 2006, 4, 957-969.	3.4	13
164	Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. International Journal of Radiation Oncology Biology Physics, 2005, 61, 830-841.	0.8	51
165	Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 426-436.	0.8	16
166	Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Medical Physics, 2005, 32, 2193-2203.	3.0	49
167	Helical tomotherapy for craniospinal radiation. British Journal of Radiology, 2005, 78, 548-552.	2.2	70
168	Tomotherapy planning of small brain tumours. Radiotherapy and Oncology, 2005, 74, 49-52.	0.6	59
169	Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review. Radiotherapy and Oncology, 2005, 75, 258.E1-258.E13.	0.6	148
170	A pilot study of regional participation in a videoconferenced multidisciplinary genitourinary tumor board. Canadian Journal of Urology, 2005, 12, 2532-6.	0.0	8
171	Asymmetric fan beams (AFB) for improvement of the craniocaudal dose distribution in helical tomotherapy delivery. Medical Physics, 2004, 31, 2443-2448.	3.0	7
172	Radiotherapy for Pediatric Central Nervous System Tumors: A Regional Cancer Centre Experience. Journal of Neuro-Oncology, 2004, 68, 285-294.	2.9	3
173	In regard to Fiorino et al.: rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953–962). International Journal of Radiation Oncology Biology Physics, 2004, 59, 912-914.	0.8	7
174	Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy. Medical Dosimetry, 2004, 29, 18-25.	0.9	17
175	Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial. Journal of Clinical Oncology, 2004, 22, 1583-1588.	1.6	757
176	Planning evaluation of radiotherapy for complex lung cancer cases using helical tomotherapy. Physics in Medicine and Biology, 2004, 49, 3675-3690.	3.0	64
177	Re: New radiotherapy technologies for meningiomas: 3D conformal radiotherapy? Radiosurgery? Sterotactic radiotherapy? Intensity modulated radiotherapy? Proton beam radiotherapy? Spot scanning proton radiation therapy? Or nothing at all? [Radiother Oncol 2004;71(3):247–249]. Radiotherapy and Oncology, 2004, 73, 251-252.	0.6	5
178	The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology, 2002, 64, 239-250.	0.6	26
179	Ki-67: a prognostic factor for low-grade glioma?. International Journal of Radiation Oncology Biology Physics, 2002, 52, 996-1001.	0.8	82
180	Nontraumatic Osteonecrosis After Chemotherapy for Testicular Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 603-606.	1.3	31

#	Article	lF	CITATIONS
181	Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Seminars in Radiation Oncology, 2001, 11, 170-180.	2.2	19
182	Simulation for localized prostate cancer: a comparison of urethrography techniques. Medical Dosimetry, 2000, 25, 145-148.	0.9	0
183	Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 1999, 45, 291-295.	0.8	35
184	Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1999, 45, 923-929.	0.8	204
185	Effects of radiation on a model of malignant glioma invasion. Journal of Neuro-Oncology, 1999, 44, 223-231.	2.9	21
186	Effects of radiation on a threeâ€dimensional model of malignant glioma invasion. International Journal of Developmental Neuroscience, 1999, 17, 643-651.	1.6	36
187	Bihemispheric malignant glioma: one size does not fit all. Journal of Neuro-Oncology, 1998, 38, 83-89.	2.9	10
188	Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 319-324.	0.8	84
189	Postoperative radiotherapy for stage I/II seminoma: results for 212 patients. International Journal of Radiation Oncology Biology Physics, 1998, 42, 313-317.	0.8	41
190	Low-grade gliomas in children: tumor volume response to radiation. Journal of Neurosurgery, 1998, 88, 969-974.	1.6	43
191	Primary intracerebral osteosarcoma: a case report. Journal of Neuro-Oncology, 1997, 32, 209-213.	2.9	13
192	Reirradiation of primary CNS tumors. International Journal of Radiation Oncology Biology Physics, 1996, 36, 433-441.	0.8	128
193	A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 1994, 29, 835-839.	0.8	156